460 related articles for article (PubMed ID: 29119276)
1. Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.
Weiss GJ; Blaydorn L; Beck J; Bornemann-Kolatzki K; Urnovitz H; Schütz E; Khemka V
Invest New Drugs; 2018 Feb; 36(1):96-102. PubMed ID: 29119276
[TBL] [Abstract][Full Text] [Related]
2. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice.
De Vita F; Ventriglia J; Febbraro A; Laterza MM; Fabozzi A; Savastano B; Petrillo A; Diana A; Giordano G; Troiani T; Conzo G; Galizia G; Ciardiello F; Orditura M
BMC Cancer; 2016 Sep; 16(1):709. PubMed ID: 27590845
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.
Ramanathan RK; Goldstein D; Korn RL; Arena F; Moore M; Siena S; Teixeira L; Tabernero J; Van Laethem JL; Liu H; McGovern D; Lu B; Von Hoff DD
Ann Oncol; 2016 Apr; 27(4):648-53. PubMed ID: 26802153
[TBL] [Abstract][Full Text] [Related]
4. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer.
Davis SL; Cardin DB; Shahda S; Lenz HJ; Dotan E; O'Neil BH; Kapoun AM; Stagg RJ; Berlin J; Messersmith WA; Cohen SJ
Invest New Drugs; 2020 Jun; 38(3):821-830. PubMed ID: 31338636
[TBL] [Abstract][Full Text] [Related]
5. Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma.
Grierson PM; Tan B; Pedersen KS; Park H; Suresh R; Amin MA; Trikalinos NA; Knoerzer D; Kreider B; Reddy A; Liu J; Der CJ; Wang-Gillam A; Lim KH
Oncologist; 2023 Feb; 28(2):e115-e123. PubMed ID: 36427020
[TBL] [Abstract][Full Text] [Related]
6. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions.
Giordano G; Pancione M; Olivieri N; Parcesepe P; Velocci M; Di Raimo T; Coppola L; Toffoli G; D'Andrea MR
World J Gastroenterol; 2017 Aug; 23(32):5875-5886. PubMed ID: 28932079
[TBL] [Abstract][Full Text] [Related]
7. Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study.
Ueno M; Morinaga S; Hashimoto Y; Umemoto K; Sasahira N; Saiura A; Seyama Y; Honda G; Ioka T; Takahashi H; Miyamoto A; Nakamori S; Unno M; Takadate T; Mizuno N; Shimizu Y; Ueno H; Sugiyama M; Fukutomi A; Shimizu S; Okusaka T; Furuse J
Pancreas; 2021 Jan; 50(1):83-88. PubMed ID: 33370027
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of gemcitabine plus S-1
Zhu Z; Tang H; Ying J; Cheng Y; Wang X; Wang Y; Bai C
Cancer Biol Med; 2023 Aug; 20(10):765-78. PubMed ID: 37646237
[TBL] [Abstract][Full Text] [Related]
9. Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study.
Wang-Gillam A; Lim KH; McWilliams R; Suresh R; Lockhart AC; Brown A; Breden M; Belle JI; Herndon J; Bogner SJ; Pedersen K; Tan B; Boice N; Acharya A; Abdiannia M; Gao F; Yoon HH; Zhu M; Trikalinos NA; Ratner L; Aranha O; Hawkins WG; Herzog BH; DeNardo DG
Clin Cancer Res; 2022 Dec; 28(24):5254-5262. PubMed ID: 36228156
[TBL] [Abstract][Full Text] [Related]
10. MR-Guided Radiation Therapy With Concurrent Gemcitabine/Nab-Paclitaxel Chemotherapy in Inoperable Pancreatic Cancer: A TITE-CRM Phase I Trial.
Kim H; Olsen JR; Green OL; Chin RI; Hawkins WG; Fields RC; Hammill C; Doyle MB; Chapman W; Suresh R; Tan B; Pedersen K; Jansen B; DeWees TA; Lu E; Henke LE; Badiyan S; Parikh PJ; Roach MC; Wang-Gillam A; Lim KH
Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):214-223. PubMed ID: 35878713
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial.
Zhang D; Benedikt Westphalen C; Quante M; Waldschmidt DT; Held S; Kütting F; Dorman K; Heinrich K; Weiss L; Boukovala M; Haas M; Boeck S; Heinemann V; Probst V
Eur J Cancer; 2024 Apr; 201():113926. PubMed ID: 38401449
[TBL] [Abstract][Full Text] [Related]
12. SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial.
Digklia A; Kollár A; Dietrich D; Kronig MN; Britschgi C; Rordorf T; Joerger M; Krasniqi F; Metaxas Y; Colombo I; Ribi K; Rothermundt C
Eur J Cancer; 2024 Jan; 197():113470. PubMed ID: 38096656
[TBL] [Abstract][Full Text] [Related]
13. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.
Wainberg ZA; Melisi D; Macarulla T; Pazo Cid R; Chandana SR; De La Fouchardière C; Dean A; Kiss I; Lee WJ; Goetze TO; Van Cutsem E; Paulson AS; Bekaii-Saab T; Pant S; Hubner RA; Xiao Z; Chen H; Benzaghou F; O'Reilly EM
Lancet; 2023 Oct; 402(10409):1272-1281. PubMed ID: 37708904
[TBL] [Abstract][Full Text] [Related]
14. Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer.
Nakano S; Komatsu Y; Kawamoto Y; Saito R; Ito K; Nakatsumi H; Yuki S; Sakamoto N
Medicine (Baltimore); 2020 Sep; 99(39):e22250. PubMed ID: 32991420
[TBL] [Abstract][Full Text] [Related]
15. Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma.
Tian Z; Zhang F; Li P; Wang J; Yang J; Zhang P; Yao W; Wang X
BMC Cancer; 2020 Jul; 20(1):698. PubMed ID: 32723378
[TBL] [Abstract][Full Text] [Related]
16. Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?
Liang C; Shi S; Meng Q; Liang D; Ji S; Zhang B; Qin Y; Xu J; Ni Q; Yu X
Cell Mol Life Sci; 2018 Mar; 75(6):1001-1012. PubMed ID: 28993833
[TBL] [Abstract][Full Text] [Related]
17. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.
Catenacci DV; Junttila MR; Karrison T; Bahary N; Horiba MN; Nattam SR; Marsh R; Wallace J; Kozloff M; Rajdev L; Cohen D; Wade J; Sleckman B; Lenz HJ; Stiff P; Kumar P; Xu P; Henderson L; Takebe N; Salgia R; Wang X; Stadler WM; de Sauvage FJ; Kindler HL
J Clin Oncol; 2015 Dec; 33(36):4284-92. PubMed ID: 26527777
[TBL] [Abstract][Full Text] [Related]
18. Partial response in non-resectable adenosquamous carcinoma of the pancreas with high tumour mutation burden treated with gemcitabine, nab-paclitaxel and pembrolizumab.
Paredes de la Fuente R; Doolin JW; Peters ML
BMJ Case Rep; 2023 Feb; 16(2):. PubMed ID: 36746516
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment.
Foucher ED; Ghigo C; Chouaib S; Galon J; Iovanna J; Olive D
Front Immunol; 2018; 9():1044. PubMed ID: 29868007
[TBL] [Abstract][Full Text] [Related]
20. The role of biliary events in treatment and survival of patients with advanced pancreatic ductal adenocarcinoma.
Gasparini G; Aleotti F; Palucci M; Belfiori G; Tamburrino D; Partelli S; Orsi G; Macchini M; Archibugi L; Capurso G; Arcidiacono PG; Crippa S; Reni M; Falconi M
Dig Liver Dis; 2023 Dec; 55(12):1750-1756. PubMed ID: 37121820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
